MTAP 결손 진행성 고형 종양에서 IDE892 단독요법 및 병용요법에 관한 연구
MTAP 결손 진행성 고형 종양 환자를 대상으로 IDE892 단독 요법 및 병용 요법의 안전성, 효능 및 약동학을 평가하는 다기관 연구
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The purpose of this study is to evaluate safety, efficacy, and PK of IDE892 as monotherapy and combination therapy in adult participants with MTAP-deleted tumors who have progressed after standard therapy and represent a high unmet need. In the current stage, the combination will be focused on IDE892 with IDE397, an oral inhibitor of methionine adenosyltransferase 2A (MAT2A), to fully exploit the vulnerabilities associated with methylthioadenosine (MTA) accumulation in MTAP-deleted tumors while maintaining a substantial therapeutic index. The mechanistic rationale for this study is discussed in the following sections.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: IDEAYA Clinical Trials
- 전화번호: +1 855 433 2246
- 이메일: IDEAYAClinicalTrials@ideayabio.com
연구 장소
-
-
Arizona
-
Goodyear, Arizona, 미국, 85338
- 모병
- City of Hope Cancer Center-Phoenix
-
연락하다:
- Amit Kulkarni, MD
- 전화번호: 612-624-9604
- 이메일: amkulkarni@coh.org
-
Phoenix, Arizona, 미국, 85054
- 모병
- Mayo Clinic Arizona
-
연락하다:
- Mitesh J. Borad, M.D.
- 전화번호: 855-776-0015
-
-
California
-
Duarte, California, 미국, 91010
- 모병
- City of Hope Cancer Center-Duarte
-
연락하다:
- Abhishek Tripathi, M.D.
- 전화번호: 626-218-9200
- 이메일: atripathi@coh.org
-
Santa Rosa, California, 미국, 95403
- 모병
- Providence Medical Foundation
-
연락하다:
- Ian Anderson, MD
- 전화번호: 707-521-3830
- 이메일: ian.anderson@providence.org
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20016
- 모병
- Johns Hopkins Sibley Memorial Hospital
-
연락하다:
- Solmaz Sahebjam, MD
- 전화번호: 202-669-6500
- 이메일: ssahebj1@jh.edu
-
연락하다:
- Mahlet Atnafu
- 전화번호: 202-669-6500
- 이메일: SibleyOncResReferral@live.johnshopkins.edu
-
-
Florida
-
Coral Springs, Florida, 미국, 33065
- 모병
- BRCR Global-Coral Springs
-
연락하다:
- Alina Quintana
- 전화번호: 561-447-0614
- 이메일: alinaq@brcrglobal.com
-
Jacksonville, Florida, 미국, 32224
- 모병
- Mayo Clinic Florida
-
연락하다:
- Conor D. O'Donnell, M.B., B.Ch., B.A.O.
- 전화번호: 855-776-0015
-
Orlando, Florida, 미국, 32827
- 모병
- Sarah Cannon Research Institute at Florida Cancer Specialists
-
연락하다:
- Elizabeth Gilmore
- 전화번호: 904-380-2410
- 이메일: Elizabeth.Griffith@Scri.com
-
Tampa, Florida, 미국, 33612
- 모병
- Moffitt Cancer Center
-
연락하다:
- Mauricio Ribeiro, MD
- 전화번호: 813-745-3242
- 이메일: mauricio.ribeiro@moffitt.org
-
연락하다:
- Anisa Gonzalez
- 전화번호: 813-745-3874
- 이메일: anisa.gonzalez@moffitt.org
-
-
Illinois
-
Zion, Illinois, 미국, 60099
- 모병
- City of Hope Cancer Center-Chicago
-
연락하다:
- Evan Pisick, M.D.
- 전화번호: 415-353-9674
- 이메일: episick@coh.org
-
-
Minnesota
-
Rochester, Minnesota, 미국, 55905
- 모병
- Mayo Clinic Rochester
-
연락하다:
- Kaushal Parikh, M.B.B.S.
- 전화번호: 855-776-0015
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68130
- 모병
- Nebraska Cancer Specialists
-
연락하다:
- Lindsey Becker, Primary Study Coordinator
- 전화번호: 402-691-5255
- 이메일: lbecker@nebraskacancer.com
-
-
New Jersey
-
East Brunswick, New Jersey, 미국, 08816
- 모병
- START Astera, LLC
-
연락하다:
- Hope Team Distribution List
- 이메일: hopeteam@startresearch.com
-
-
New York
-
New York, New York, 미국, 10032
- 모병
- Columbia University Irving Medical Center
-
연락하다:
- Nurse Navigation Team: Contact for All Patient Referrals
- 전화번호: 212-342-5162
- 이메일: cancerclinicaltrials@cumc.columbia.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19107
- 모병
- Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University
-
연락하다:
-
연락하다:
- askphase1@jefferson.edu
- 전화번호: 215-586-0199
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- Sarah Cannon Research Institute
-
연락하다:
- Alydia Miller
- 전화번호: 615-927-2212
- 이메일: alydia.miller@scri.com
-
연락하다:
- Sarah Cannon Institute
- 전화번호: 844-482-4812
- 이메일: asksarah@sarahcannon.com
-
-
Texas
-
Fort Worth, Texas, 미국, 76104
- 모병
- START Dallas Fort Worth
-
연락하다:
- Kasie Newton
- 전화번호: 682-350-3010
- 이메일: kasie.newton@startresearch.com
-
Houston, Texas, 미국, 77030
- 모병
- MD Anderson
-
연락하다:
- Jordi Rodon Ahnert, MD, PhD
- 전화번호: 713-563-1930
- 이메일: JRodon@mdanderson.org
-
Houston, Texas, 미국, 77054
- 모병
- NEXT Oncology Houston
-
연락하다:
- Emma Morales
- 전화번호: 832-384-7912
- 이메일: emorales@nextoncology.com
-
Irving, Texas, 미국, 75039
- 모병
- NEXT Oncology Dallas
-
연락하다:
- Mofopefoluwa Akinwale
- 전화번호: 972-893-8800
- 이메일: fakinwale@nextoncology.com
-
-
Utah
-
West Valley City, Utah, 미국, 84119
- 모병
- START Mountain Region, LLC
-
연락하다:
- Marie Asay, Director, Nursing
- 전화번호: 801-907-4770
- 이메일: marie.asay@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, 미국, 22031
- 모병
- NEXT Oncology Virginia
-
연락하다:
- Maybelle De La Rosa
- 전화번호: 703-783-4518
- 이메일: mdelarosa@nextoncology.com
-
-
Washington
-
Seattle, Washington, 미국, 98104
- 모병
- Swedish Cancer Institute
-
연락하다:
- Siddhartha Devarakonda, MD
- 전화번호: 206-386-2424
- 이메일: siddhartha.devarakonda@swedish.org
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Are ≥ 18 years of age (or the minimum age of consent in accordance with local regulations) at the time of signing the ICF.
- Have a histologically confirmed diagnosis of a locally advanced recurrent or metastatic solid tumor type of interest with MTAP deletion (for dose escalation: mesothelioma [pleural or peritoneal], gastroesophageal cancers [squamous and adenocarcinoma of esophagus, gastric adenocarcinoma, gastroesophageal junction cancers], pancreatic adenocarcinoma and biliary tract carcinomas (intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder cancer), NSCLC [adenocarcinoma, squamous cell carcinoma, and adeno-squamous] or UC [including mixed urothelial-squamous histology]; for dose expansion: NSCLC that has progressed on at least one prior line of treatment and for which additional effective standard therapy is not available or for which the participant is not a candidate due to intolerance).
- Are willing and able to provide blood/tumor tissue samples for biomarker testing. An archival tumor tissue specimen must be provided for central confirmation of MTAP loss.
- Must be willing and able to provide the blood/serum/plasma samples
- Have evidence of homozygous loss of MTAP or MTAP deletion (pre-screening available after signing pre-screening ICF)
- Have at least 1 measurable lesion according to RECIST version 1.1
- Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1
- Have life expectancy > 3 months
- Have adequate bone marrow and organ function
- Able to swallow and retain orally administered study drug/IMP.
- Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures
- Male and female: willing to use contraception
Exclusion Criteria:
- Known symptomatic brain metastases requiring supraphysiologic doses of systemic corticosteroids
- Have a known primary central nervous system (CNS) malignancy
- Have had other malignancies within 2 years prior to the first dose, with some exceptions
- Impaired cardiac function or clinically significant cardiac diseases
- Have presence of uncontrolled pleural, peritoneal, or pericardial effusion within 2 weeks before the first study dose, requiring recurrent drainage procedures or an indwelling drainage catheter
- Have a history of severe infections within 4 weeks prior to the start of study treatment
- Hypertension (e.g., > 150/100 mmHg) that cannot be controlled by medications despite optimal medical therapy
- Other acute or chronic medical or psychiatric condition
- Have a history of immunodeficiency, with a positive human immunodeficiency virus(HIV) test at screening
- Known or suspected viral hepatitis with a positive test at screening
- Had an adverse reaction to a previous antitumor treatment that has not recovered to CTCAE Grade ≤ 1
- Have received chemotherapy within 4 weeks of the first dose of IMP; immunotherapy or biologic targeted antitumor treatments within 2 weeks before the first dose of IMP; small molecule inhibitors within 2 weeks before the first dose of IMP, or other investigational products within 4 weeks
- Current radiation-related toxicity or radiation therapy within 2 weeks before the first dose of IMP
- Administration of any of the following within 2 weeks before the first dose of IDE892 as a monotherapy: Strong inhibitors or inducers of cytochrome P450, Strong inhibitors of P-glycoprotein, Narrow therapeutic index and sensitive substrates of multidrug and toxin extrusion (MATE)1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and breast cancer resistance protein
- Administration of any of the following within 2 weeks before the first dose of IDE892: Strong inhibitors or inducers of CYP3A4/5, Strong inhibitors of P-gp and/or BCRP, Narrow therapeutic index and sensitive substrates of MATE1 and MATE2-K, Narrow therapeutic index and sensitive substrates of P-gp and BCRP
- Use of proton pump inhibitors (PPIs) within 7 days prior to the first dose of IMP or planned use during the study
- Use of drugs with known risk for QT prolongation within 2 weeks prior to the first dose of IDE892
- Previous treatment with a Amethionine adenosyltransferase 2A (MAT2A) inhibitor and/or Protein arginine N-methyltransferase (PRMT) inhibitor
- Major surgery within 4 weeks before study entry
- Prior irradiation to > 25% of the bone marrow
- Known or suspected hypersensitivity to IDE892
Disease-Specific Eligibility Criteria Eligibility Criteria for Participants with NSCLC (All Parts)
- Must have histologically confirmed diagnosis of advanced or metastatic NSCLC that has progressed after prior treatment with platinum chemotherapy and a PD-1/PD-L1 inhibitor (unless contraindicated or participant developed intolerance) in the metastatic setting
- Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease.
- If considered standard of care and available, participants whose cancers have proven targetable oncogene alterations must have had disease progression on (unless contraindicated or participant developed intolerance) at least 1 prior line containing appropriate targeted therapy.
Eligibility Criteria for Participants with Urothelial Cancer (Bladder and Upper Urinary Tract), Mesothelioma (Pleural or Peritoneal), Pancreatic Adenocarcinoma or Biliary Tract Carcinomas (Intrahepatic and Extrahepatic Cholangiocarcinoma, and Gallbladder Cancer) (Parts 1 and 3)
- Must have histologically confirmed diagnosis of advanced or metastatic UC, mesothelioma, gastroesophageal cancer or pancreatic and biliary tract tumors
- Must have progressed following at least 1 prior line of therapy
- Treatment with no more than 3 prior lines in the setting of advanced or metastatic disease
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Part 1: IDE892 Monotherapy Dose Escalation (MTAP-deleted advanced solid tumors)
Participants with advanced or metastatic solid tumors harboring MTAP deletion (including mesothelioma, gastroesophageal cancers, pancreatic and biliary tract tumors, non-small cell lung cancer, and urothelial cancer) will receive IDE892. Dose levels will be escalated sequentially using a Bayesian Optimal Interval (BOIN) design to evaluate safety, tolerability, and to determine the maximum tolerated dose and/or recommended dose for expansion. PK and pharmacodynamics (PD) and preliminary antitumor activity will also be assessed. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. |
|
실험적: Part 2: IDE892 Monotherapy Dose Expansion (MTAP-Deleted NSCLC)
Participants with advanced or metastatic NSCLC with MTAP deletion will receive IDE892. One or more dose levels at or below the maximum tolerated dose from Part 1 will be further evaluated to determine the recommended Phase 2 dose and to assess antitumor activity. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. |
|
실험적: Part 3: IDE892 + IDE397 Combination Dose Escalation (MTAP-Deleted Solid Tumors)
Participants with advanced or metastatic solid tumors harboring MTAP deletion (including mesothelioma, gastroesophageal cancers, pancreatic and biliary tract tumors, non-small cell lung cancer, and urothelial cancer) will receive IDE892 in combination with IDE397. Dose levels will be escalated using a modified toxicity probability interval (mTPI) design to evaluate safety, tolerability, and to determine the maximum tolerated dose and/or recommended dose for expansion. PK, PD, and preliminary antitumor activity will also be assessed. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors. |
|
실험적: Part 4: IDE892 + IDE397 Combination Dose Expansion (MTAP-Deleted NSCLC)
Participants with advanced or metastatic NSCLC with MTAP deletion will receive IDE892 in combination with IDE397. One or more dose levels at or below the maximum tolerated dose from Part 3 will be further evaluated to determine the recommended Phase 2 dose and to assess antitumor activity. |
IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Dose-limiting Toxicities (DLTs) of IDE892 (Parts 1 and 3)
기간: 21 days following the first dose of IDE892 (each cycle is 21 days)
|
Incidence of DLTs of IDE892 will be determined in Parts 1 and 3 |
21 days following the first dose of IDE892 (each cycle is 21 days)
|
|
Incidence of AEs and SAEs (Parts 1, 2, 3, and 4)
기간: From first dose until 28 days after last dose (each cycle is 21 days)
|
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) (graded based on Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) will be determined in Parts 1, 2, 3, and 4. |
From first dose until 28 days after last dose (each cycle is 21 days)
|
|
Objective response rate (ORR) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Parts 2 and 4)
기간: Approximately 2 years
|
Objective response rate (ORR: best objective response of complete response [CR] + partial response [PR]) and duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the Investigator |
Approximately 2 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall response rate (ORR) and duration of response (DOR) per RECIST version 1.1 (Parts 1 and 3)
기간: Approximately 2 years
|
ORR and DOR per RECIST version 1.1 as assessed by the Investigator |
Approximately 2 years
|
|
Disease control rate (DCR) and duration of stable disease per RECIST version 1.1 (Parts 1, 2, 3, and 4)
기간: Approximately 2 years
|
Disease control rate (disease control rate [DCR]: CR + PR + stable disease [SD]) and duration of SD per RECIST version 1.1 as assessed by the Investigator |
Approximately 2 years
|
|
Maximum Observed Plasma Concentration (Cmax) (Parts 1, 2, 3, and 4)
기간: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Cmax is the highest observed plasma concentration of the study drug following administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time to Maximum Observed Concentration (Tmax)
기간: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Time to Maximum Observed Concentration (Tmax) after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast)
기간: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
AUClast reflects total drug exposure from dosing until the last measurable concentration after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time of Last Quantifiable Concentration (Tlast)
기간: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Tlast is the time at which the final measurable drug concentration is observed after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf)
기간: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
AUCinf represents total drug exposure extrapolated to infinite time after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Terminal Elimination Half-Life (t½)
기간: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
t½ is the time required for the plasma concentration of the drug to decrease by half during the terminal elimination phase after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Maximum Observed Plasma Concentration at Steady State (Cmax,ss)
기간: Cycle 1 Day 15 (each cycle is 21 days)
|
Cmax,ss is the maximum observed plasma concentration after achieving steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Time to Maximum Concentration at Steady State (Tmax,ss)
기간: Cycle 1 Day 15 (each cycle is 21 days)
|
Tmax,ss is the time from dosing to Cmax at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Trough Plasma Concentration at Steady State (Ctrough)
기간: Cycle 1 Day 15 (each cycle is 21 days)
|
Ctrough is the concentration obtained immediately prior to the next scheduled dose at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUCtau)
기간: Cycle 1 Day 15 (each cycle is 21 days)
|
AUCtau represents drug exposure over one full dosing interval at steady state after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 15 (each cycle is 21 days)
|
|
Apparent Clearance (CL/F)
기간: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
CL/F is the apparent clearance of the drug after extravascular dosing after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Apparent Volume of Distribution (Vz/F)
기간: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Vz/F is the apparent volume of distribution following extravascular dosing after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
|
Accumulation Ratio (Rac)
기간: Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
Rac is calculated as the ratio of AUC or Cmax at steady state compared with first dose, reflecting drug accumulation after administration of IDE892 as a single agent or in combination with IDE397 |
Cycle 1 Day 1 and Cycle 1 Day 15 (each cycle is 21 days)
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Edward Chan, MD, IDEAYA Biosciences
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
- 비뇨생식기 질환
- 내분비계 질환
- 병리학적 과정
- 비뇨생식기 신생물
- 부위별 신생물
- 신생물
- 남성 비뇨 생식기 질환
- 비뇨기과 질환
- 여성 비뇨 생식기 질환
- 여성 비뇨 생식기 질환 및 임신 합병증
- 질병 속성
- 호흡기 질환
- 조직학적 유형에 따른 신생물
- 위장관 신생물
- 소화계 신생물
- 소화기계 질환
- 위장병
- 폐 질환
- 내분비샘 신생물
- 두경부 신생물
- 췌장 질환
- 신생물, 선상 및 상피
- 호흡기 신생물
- 흉부 신생물
- 종양 과정
- 식도 질환
- 폐 신생물
- 선종
- 신생물, 중피
- 흉막 신 생물
- 비뇨기과 신생물
- 암종
- 신생물, 편평 세포
- 방광 질환
- 암종, 편평 세포
- 식도 신생물
- 병리학적 상태, 징후 및 증상
- 식도 편평 세포 암종
- 중피종, 악성
- 회귀
- 중피종
- 신생물 전이
- 췌장 신생물
- 방광 신생물
- 암종, 과도기 세포
- 식도 선암종
기타 연구 ID 번호
기타 연구 ID 번호
- IDE892-001
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .